GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Verona Pharma plc
Verona Pharma's shares, a biotech company, are driven by hopes for its lead drug for chronic obstructive pulmonary disease (COPD). The price chart reflects high volatility and dependence on clinical trial results and regulatory decisions.
Share prices of companies in the market segment - Pharma other
Verona Pharma operates in the biotechnology segment, focusing on drugs for respiratory diseases. We classify it in the Other Pharmaceuticals sector. The chart below reflects the dynamics of this entire innovative, yet risky, pharmaceutical segment.
Broad Market Index - GURU.Markets
Verona Pharma is a biopharmaceutical company focused on developing treatments for respiratory diseases such as chronic obstructive pulmonary disease (COPD). It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
VRNA - Daily change in the company's share price Verona Pharma plc
The daily price change for Verona Pharma, which develops drugs for respiratory diseases, demonstrates its high volatility. The chart of these fluctuations is unspectacular, but it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma other
Verona Pharma plc is a biotech company. This chart highlights the sector's extreme volatility. Comparison with VRNA's performance, which hinges on the results of clinical trials of its respiratory disease drugs, helps assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Verona Pharma is a biopharmaceutical company specializing in the treatment of respiratory diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Verona Pharma's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Verona Pharma plc
Verona Pharma is a pharmaceutical company developing new drugs. Its shares, like many in the sector, are volatile and react to news about clinical trials. These scientifically driven movements are part of the overall stock market landscape.
Annual dynamics of market capitalization of the market segment - Pharma other
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of respiratory diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs in this area.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Verona Pharma is a clinical-stage biotech whose fate depends on the success of its research, not the state of the economy. Its chart is a history of expectations and drug news, not a reflection of market cycles. Its stock price lives in a world of its own, where the key events are regulatory decisions, not inflation or GDP data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Verona Pharma plc
Verona Pharma, a biopharmaceutical company focused on respiratory diseases, has sharp monthly fluctuations reflecting news about clinical trials of its lead drug candidate, a typical dynamic for biotech companies in the development stage.
Monthly dynamics of market capitalization of the market segment - Pharma other
This chart reflects the dynamics of the biotech sector. For Verona, a late-stage company, it's the backdrop. Its movements reflect investor anticipation surrounding the potential approval of its COPD drug, which could be a major event in its history.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Verona Pharma is a biotech company whose fate depends on the success of its drugs. The company's shares move not in sync with the market, but rather with news about clinical trials. Any breakthrough or failure causes sharp fluctuations, ignoring overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Verona Pharma plc
Verona Pharma is a biotech company developing drugs to treat respiratory diseases. Its weekly stock price exhibits the high volatility typical of biotech companies and reacts sharply to news about clinical trials.
Weekly dynamics of market capitalization of the market segment - Pharma other
Verona Pharma is a biotech company whose fate hinges on a single drug. Comparing its weekly performance to the biotech sector is pointless. The chart will show how binary events—news about clinical trials or an FDA decision—drive its shares up or down, living in a separate universe.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Shares of Verona Pharma, a biotech company, exist in a world of their own, far removed from macroeconomic news. Their performance is determined by clinical trial data. A comparison chart with the S&P 500 clearly demonstrates how the stock can move regardless of the broader market.
Market capitalization of the company, segment and market as a whole
VRNA - Market capitalization of the company Verona Pharma plc
Verona Pharma's market capitalization chart is a classic biotech story, full of hope. Its dynamics depend entirely on the results of clinical trials and the potential approval of its lead drug for chronic obstructive pulmonary disease (COPD). Every fluctuation is an investor reaction to news that can either make or break its value.
VRNA - Share of the company's market capitalization Verona Pharma plc within the market segment - Pharma other
Verona Pharma is a biopharmaceutical company focused on developing treatments for respiratory diseases such as COPD. Its sector share reflects investor expectations for its lead drug candidate. The chart below illustrates market confidence in the company's ability to carve out a niche in the treatment of lung diseases.
Market capitalization of the market segment - Pharma other
Verona Pharma is a biopharmaceutical company focused on developing treatments for chronic respiratory diseases. The chart below shows the overall market capitalization of the pharmaceutical sector. It helps assess the scale of the market Verona is targeting and the potential of its drugs if clinical trials are successful.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's hope for millions of people with chronic respiratory diseases. Verona Pharma is developing drugs to treat COPD. Its stock chart is a classic biotech story, with market caps reacting sharply to clinical trial results. This is a line backed by years of research and patient hope.
Book value capitalization of the company, segment and market as a whole
VRNA - Book value capitalization of the company Verona Pharma plc
For Verona Pharma, book value is its intellectual property for respiratory drugs and the capital raised for clinical trials. This represents the scientific foundation pending regulatory approval. The chart below shows how trial news and additional funding shaped this biotech company's capital base.
VRNA - Share of the company's book capitalization Verona Pharma plc within the market segment - Pharma other
Verona Pharma develops drugs for the treatment of respiratory diseases. Currently, its main assets are scientific data and patents, not production lines. The chart shows a very small share of physical assets, typical for a biotech company focused on clinical research.
Market segment balance sheet capitalization - Pharma other
Verona Pharma, a biopharmaceutical company, is in the late stages of development. Its business is currently lightweight and focused on R&D. If successful, it will have to build or lease capital-intensive commercial and manufacturing infrastructure, which will change its profile.
Book value of all companies included in the broad market index - GURU.Markets
Verona Pharma's book value is not its plants, but primarily its intellectual property and clinical trial data for drugs used to treat respiratory diseases. The company's assets are the capitalized results of years of research. The chart below shows how these scientific assets are valued.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Verona Pharma plc
Verona Pharma's book value is the capitalized cost of R&D. Its entire market value is a premium on hope, a bet investors make that its COPD drug will successfully pass all trials and be approved. The chart is a visualization of these hopes in anticipation of key news.
Market to book capitalization ratio in a market segment - Pharma other
Verona Pharma is a biopharmaceutical company focused on developing drugs for the treatment of respiratory diseases. Its valuation depends almost entirely on the success of clinical trials and the future commercial potential of its lead drug candidate.
Market to book capitalization ratio for the market as a whole
Verona Pharma is a biopharmaceutical company focused on treating respiratory diseases. Its market valuation depends almost entirely on the success of its lead drug's clinical trials. It's a classic example of biotech, where expectations for the future create a market cap that bears almost no relation to its current book value.
Debts of the company, segment and market as a whole
VRNA - Company debts Verona Pharma plc
Verona Pharma, a clinical-stage biopharmaceutical company developing drugs to treat respiratory diseases, uses debt and equity to finance its research. This chart shows how the company raises funds to conduct expensive clinical trials necessary to obtain regulatory approval and bring its product to market.
Market segment debts - Pharma other
Verona Pharma is a clinical-stage biotech developing drugs for respiratory diseases. For companies like this, revenue is nonexistent, and R&D costs are enormous. Debt is a method of financing until regulatory approval is obtained. This chart shows how dependent the company is on external capital for survival and success.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Verona Pharma plc
Verona Pharma is a biopharmaceutical company focused on treating respiratory diseases. Drug development is a long and expensive process. This chart shows the extent to which the company relies on debt to finance clinical trials. It directly reflects the financial risk before commercialization of its lead drug.
Market segment debt to market segment book capitalization - Pharma other
Verona Pharma is a biopharmaceutical company focused on developing drugs for the treatment of respiratory diseases. Late-stage clinical trials require significant funding. The chart shows how the company's debt burden relates to the risks and overall market capitalization of the entire biotech sector.
Debt to book value of all companies in the market
Verona Pharma, a biopharmaceutical company, finances its expensive clinical trials. This chart allows us to assess the scale of these risky investments by comparing the company's debt to the total capitalization of the entire stock market. This places the risks of biotech in a broader economic context.
P/E of the company, segment and market as a whole
P/E - Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company developing drugs to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD). This chart reflects investor expectations. The company's valuation is based not on current profits, but on the potential of its lead drug to become a new standard of care for millions of patients.
P/E of the market segment - Pharma other
Verona Pharma develops drugs to treat respiratory diseases such as COPD. This chart shows the average valuation for the biotech sector. It emphasizes that Verona's valuation is based not on current profits, but on expectations from clinical trials and the potential of its drug to become a new standard of care.
P/E of the market as a whole
Verona Pharma is a biopharmaceutical company focused on developing drugs to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD). This chart shows the overall risk appetite in the biotech industry. Verona's valuation, however, depends almost entirely on clinical trial results and regulatory decisions regarding its key drug.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Verona Pharma plc
Verona Pharma is a biopharmaceutical company focused on developing drugs to treat respiratory diseases such as COPD. This chart reflects investor expectations for the success of its clinical trials. The indicator's dynamics essentially assess the likelihood of approval and the commercial potential of its lead drug.
%20P%2FE%20Verona%20Pharma%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Verona-Pharma-plc&v=1772626636157 "Chart of the company's future (projected) P/E Verona Pharma plc")
Future (projected) P/E of the market segment - Pharma other
Verona Pharma is a biopharmaceutical company focused on developing treatments for respiratory diseases such as chronic obstructive pulmonary disease (COPD). This chart shows profitability expectations for the sector. It helps understand how the market perceives the clinical prospects of the company's lead drug and its market potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-other&v=1772626636165 "Future (projected) P/E graph of the market segment - Pharma other")
Future (projected) P/E of the market as a whole
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing drugs to treat respiratory diseases such as COPD. This chart shows investors' risk appetite. For a company whose future success depends on clinical trial results, it reflects the market's willingness to fund long-term medical research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772626636195 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing drugs for the treatment of respiratory diseases, such as COPD. The financial indicators presented here reflect research and development expenses. Future revenue is entirely dependent on the successful completion of trials and approval of its lead candidate.
Profit of companies in the market segment - Pharma other
Verona Pharma is a clinical-stage biopharmaceutical company focused on treating respiratory diseases such as chronic obstructive pulmonary disease (COPD). Its future depends on the success of clinical trials. This chart highlights the risks and potentially high returns in the biotech sector, where one successful drug can change everything.
Overall market profit
Verona Pharma is a late-stage biopharmaceutical company developing drugs for the treatment of respiratory diseases. Its future success depends entirely on the approval and commercial launch of its lead candidate. It is a classic example of a biotech company whose value reflects not current revenues, but the expectation of a scientific breakthrough.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Verona Pharma plc
Verona Pharma is a biopharmaceutical company focused on developing drugs for the treatment of respiratory diseases, primarily chronic obstructive pulmonary disease (COPD). The earnings forecast in this chart reflects analyst expectations for the successful approval and commercial launch of its lead drug candidate.
%20profit%20of%20the%20company%20Verona%20Pharma%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Verona-Pharma-plc&v=1772626636343 "Graph of future (projected) profit of the company Verona Pharma plc")
Future (predicted) profit of companies in the market segment - Pharma other
Verona Pharma is a biopharmaceutical company focused on developing treatments for respiratory diseases such as chronic obstructive pulmonary disease (COPD). This chart shows revenue projections for the pharmaceutical sector, providing context for assessing the potential success of Verona's clinical developments and their future commercial potential.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-other&v=1772626636390 "Graph of future (predicted) profits of companies in a market segment - Pharma other")
Future (predicted) profit of the market as a whole
Verona Pharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of respiratory diseases. Its value and prospects depend on the success of clinical trials. This graph, reflecting market sentiment, influences the availability of financing for biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772626636449 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Verona Pharma plc
Verona Pharma is a biopharmaceutical company in late-stage development of a drug for the treatment of chronic obstructive pulmonary disease (COPD). This chart reflects investor expectations for future sales. Revenue estimates are based on the approval and commercial success of its lead candidate.
P/S market segment - Pharma other
Verona Pharma plc is a clinical-stage biopharmaceutical company focused on the treatment of respiratory diseases, such as chronic obstructive pulmonary disease (COPD). Future revenue depends on the success of its drugs. This chart reflects investor expectations for biotech companies, allowing one to assess Verona Pharma's potential.
P/S of the market as a whole
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing drugs to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD). This chart helps understand how the market values development-stage biotech companies whose future revenue depends on the success of clinical trials.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Verona Pharma plc
Verona Pharma is a biopharmaceutical company developing drugs to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD). This chart shows the company's estimated future sales, reflecting investor expectations for the success of its clinical trials and market launch.
%20P%2FS%20Verona%20Pharma%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Verona-Pharma-plc&v=1772626636626 "The graph of the company's future (projected) P/S Verona Pharma plc")
Future (projected) P/S of the market segment - Pharma other
Verona Pharma is a biopharmaceutical company focused on developing drugs to treat respiratory diseases such as chronic obstructive pulmonary disease (COPD). Its lead candidate is in late-stage development. This timeline reflects investor expectations for the potential success of its drug and future sales.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20other&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-other&v=1772626636663 "Future (projected) P/S market segment graph - Pharma other")
Future (projected) P/S of the market as a whole
Verona Pharma is a biopharmaceutical company developing drugs for the treatment of respiratory diseases. Its future revenue depends on the success of clinical trials and the commercialization of its lead candidate. This general expectations chart for VRNA is not a direct driver. The company's value is determined by scientific data and regulatory decisions, not by market cycles.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772626636706 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Verona Pharma plc
This graph illustrates a pharmaceutical company's progress through clinical development. For Verona Pharma, which focuses on treating respiratory diseases, it will show minimal values. Significant changes in the dynamics will occur only after the successful approval and launch of their lead drug candidate.
Sales of companies in the market segment - Pharma other
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing drugs to treat respiratory diseases such as COPD. Its success depends on trial results and regulatory approval. This graph reflects the market potential and unmet needs in chronic lung disease treatment, where Verona could find a niche.
Overall market sales
Verona Pharma is a late-stage biotech company developing a drug for chronic obstructive pulmonary disease (COPD). The potential success of its drug could unlock a huge market. The company exemplifies how pharmaceutical innovation can not only improve people's lives but also create new economic value.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Verona Pharma plc
Verona Pharma is a biopharmaceutical company focused on developing drugs for the treatment of respiratory diseases, such as chronic obstructive pulmonary disease (COPD). Future sales projections are dependent on the success of clinical trials and potential approval of its lead candidate.
%20sales%20of%20the%20company%20Verona%20Pharma%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Verona-Pharma-plc&v=1772626636806 "Schedule of future (projected) sales of the company Verona Pharma plc")
Future (projected) sales of companies in the market segment - Pharma other
Verona Pharma plc is a biopharmaceutical company focused on treating respiratory diseases. The forecast for the pharmaceutical sector in this area shows high unmet demand, reflecting the significant need for new treatments for chronic obstructive pulmonary disease (COPD) and other similar conditions.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-other&v=1772626636831 "Schedule of future (projected) sales of companies in the market segment - Pharma other")
Future (projected) sales of the market as a whole
Verona Pharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of respiratory diseases. Its value and prospects depend entirely on the success of clinical trials and subsequent regulatory approval. The overall economic situation, reflected in this chart, does not affect patient demand for treatment, but it does influence the investment climate in biotech.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772626636894 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Verona Pharma plc
Verona Pharma, a clinical-stage biopharmaceutical company, shows its path to commercialization in this chart. Current profitability is likely negative due to the development costs of its lead candidate for chronic obstructive pulmonary disease (COPD). Success will depend on trial results and regulatory approval.
Market segment marginality - Pharma other
Verona Pharma is a late-stage biopharmaceutical company developing drugs for chronic respiratory diseases such as COPD. This chart shows the average profitability in the pharmaceutical industry. The potential success of its lead candidate in this large market could allow the company to achieve significantly higher-than-average profitability in the future.
Market marginality as a whole
Verona Pharma plc is a biopharmaceutical company focused on developing drugs for the treatment of respiratory diseases. This chart shows the company's overall profit margin. Compared to this, Verona is a classic clinical-stage biotech story. The company has no revenue and is losing money, and its future depends on the success of clinical trials and regulatory approval.
Employees in the company, segment and market as a whole
Number of employees in the company Verona Pharma plc
Verona Pharma is a biopharmaceutical company in the late-stage development of a drug for chronic respiratory diseases such as COPD. The growth of its small but focused team, as demonstrated by this graph, would be a direct indicator of its progress toward commercialization and the creation of the infrastructure for its launch.
Share of the company's employees Verona Pharma plc within the market segment - Pharma other
Verona Pharma is a late-stage biopharmaceutical company focused on drugs for the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD). This chart illustrates its scientific focus, reflecting the percentage of pulmonologists and clinical research specialists the company attracts in this area.
Number of employees in the market segment - Pharma other
Verona Pharma is a biopharmaceutical company in late-stage development of a drug for chronic obstructive pulmonary disease (COPD). This graph shows the potential for treating respiratory diseases. A successful launch will require hiring a full team to commercialize and bring the product to market.
Number of employees in the market as a whole
Verona Pharma is a biopharmaceutical company focused on developing drugs for the treatment of respiratory diseases. Its success depends on clinical trial results and regulatory approval. A stable economic environment, reflected in this chart, is essential for attracting the investment needed to conduct costly research.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Verona Pharma plc (VRNA)
Verona Pharma is a biotech company on the cusp of commercializing its drug for chronic obstructive pulmonary disease (COPD). This chart shows how the market views its future potential. Its high market capitalization per employee suggests investors are betting that a small team can bring a new blockbuster to market.
%20of%20the%20company%20Verona%20Pharma%20plc%20(VRNA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Verona-Pharma-plc-VRNA&v=1772626637241 "Chart of market capitalization per employee (in thousands of dollars) of the company Verona Pharma plc (VRNA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma other
Verona Pharma is a biotech company in the late-stage development of a drug (Ensifentrine) for the treatment of chronic obstructive pulmonary disease (COPD). This chart shows the average market capitalization per employee in the sector. It reflects market expectations for the success of their key drug, estimated based on the company's relatively small R&D staff.
%20by%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-other&v=1772626637253 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma other")
Market capitalization per employee (in thousands of dollars) for the overall market
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing drugs for respiratory diseases. Its valuation depends on the success of clinical trials. This chart shows a very high valuation per employee, typical for biotech companies where a small team of scientists is working on a potential blockbuster.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772626637282 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Verona Pharma plc (VRNA)
Verona Pharma is a biotech company in the late stage of developing a drug for the treatment of COPD (chronic obstructive pulmonary disease). It is an R&D company with no commercial product yet. This metric will be negative, reflecting its "burn." It shows how much the company spends on each scientist and employee during clinical trials and preparation for a potential launch.
%20Chart%20Verona%20Pharma%20plc%20(VRNA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Verona-Pharma-plc-VRNA&v=1772626637345 "Company Profit Per Employee (in thousands of dollars) Chart Verona Pharma plc (VRNA)")
Profit per employee (in thousands of dollars) in the market segment - Pharma other
Verona Pharma is a biotech company in the R&D stage (developing a drug for COPD). This chart shows the benchmark for "Pharma" (R&D). The average profit per employee in this sector (venture R&D) is *negative*. This benchmark reflects the "burning" of cash in the hopes of one or two mega-successes.
%20in%20the%20market%20segment%20-%20Pharma%20other&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-other&v=1772626637392 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma other")
Profit per employee (in thousands of dollars) for the market as a whole
Verona Pharma is a clinical-stage biopharmaceutical company developing drugs for the treatment of respiratory diseases. Currently, the company has no revenue and incurs significant R&D expenses. This chart reflects a typical biotech situation: negative profit per employee in anticipation of a potential breakthrough and future commercial success.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772626637415 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Verona Pharma plc (VRNA)
Verona Pharma is a biopharmaceutical company in the late-stage development of a drug for the treatment of respiratory diseases. The current graph reflects the company's status prior to commercialization. If its product is successful, this figure could grow significantly, demonstrating the potential revenue generated by a small, focused team.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Verona-Pharma-plc-VRNA&v=1772626637486 "Sales chart per company employee Verona Pharma plc (VRNA)")
Sales per employee in the market segment - Pharma other
Verona Pharma is a biotech company in late-stage development of a drug for the treatment of COPD (chronic obstructive pulmonary disease). While this metric is likely low at this point, it will become critical after commercialization. It will demonstrate how effectively their team can bring the new drug to a competitive market.
Sales per employee for the market as a whole
Verona Pharma is a clinical-stage biotech company focused on developing drugs for respiratory diseases such as COPD. This chart shows the revenue (if any) generated by its small staff of scientists. For an R&D company, this metric isn't key until a drug is approved; it likely reflects grants or partnership payments.
Short shares by company, segment and market as a whole
Shares shorted by company Verona Pharma plc (VRNA)
Verona Pharma is a clinical-stage biotech company developing drugs for the treatment of respiratory diseases, primarily COPD (chronic obstructive pulmonary disease). This chart shows bearish bets. Bears are betting that the company's key drug will not demonstrate sufficient efficacy in trials or will not receive regulatory approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Verona-Pharma-plc-VRNA&v=1772626637596 "Short Shares Chart for the Company Verona Pharma plc (VRNA)")
Shares shorted by market segment - Pharma other
Verona Pharma is a biotech company focused on developing drugs to treat respiratory diseases such as COPD. This chart shows overall short positions across the biotech sector. The high short interest in the sector reflects general market skepticism toward the sector, possibly due to recent clinical trial failures or funding issues.
Shares shorted by the overall market
Verona Pharma is a biotech company whose fate hinges on a single drug for the treatment of COPD (chronic obstructive pulmonary disease). This is a classic binary risk. This chart reflects speculative bets. Bears are shorting VRNA, unsure of the success of clinical trials or FDA approval. Any negative news could devalue the company.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Verona Pharma plc (VRNA)
Verona Pharma is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. This chart for VRNA can soar above 70 on positive trial data. Oversold territory (<30) often reflects research setbacks or general risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Verona-Pharma-plc-VRNA&v=1772626637774 "RSI 14 indicator chart for the company's stock Verona Pharma plc (VRNA)")
RSI 14 Market Segment - Pharma other
Verona Pharma (VRNA) is a biotech company focused on developing drugs for chronic respiratory diseases (COPD). The RSI_14_Seg for "Pharma other" (biotech) reflects the overall sentiment. It helps us understand whether VRNA's volatility is a reaction to its clinical trials or general sector overheating.
RSI 14 for the overall market
Verona Pharma is a biopharmaceutical company focused on developing drugs to treat respiratory diseases such as COPD. Their success depends on trial results. This market sentiment chart shows risk appetite. For biotechs with a single key drug, market euphoria can attract capital, but panic forces investors to avoid such binary bets.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast VRNA (Verona Pharma plc)
Verona Pharma is a late-stage biotech company. Their lead candidate, Ensifentrine, is a potential new class of inhaled drugs for the treatment of COPD. This chart shows the average 12-month target from analysts, reflecting their assessment of the drug's likelihood of approval and its commercial potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-VRNA-Verona-Pharma-plc&v=1772626637875 "A chart showing analyst consensus forecasts for the expected stock price. VRNA (Verona Pharma plc)")
The difference between the consensus estimate and the actual stock price VRNA (Verona Pharma plc)
Verona Pharma is a biotech company focused on developing drugs to treat chronic respiratory diseases such as COPD. This chart shows the difference between the market valuation and the analyst consensus estimate. It highlights the potential experts see in their lead drug candidate.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-VRNA-Verona-Pharma-plc&v=1772626637927 "A chart showing the difference between the consensus forecast and the actual stock price. VRNA (Verona Pharma plc)")
Analyst consensus forecast for stock prices by market segment - Pharma other
Verona Pharma is a clinical-stage biotech company focused on developing drugs for respiratory diseases such as COPD. This chart shows analysts' overall expectations for the pharmaceutical sector. It reflects whether experts believe in the success of biotech companies' R&D pipelines.
Analysts' consensus forecast for the overall market share price
Verona Pharma is a biotech company with only one hope. Their entire success depends on the launch of a single drug for COPD. Market expectations, visible in this chart, represent their risk appetite. In a downturn (pessimism), investors are reluctant to fund companies with one trick unless sales are proven.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Verona Pharma plc
Verona Pharma is a late-stage biotech focused on treating respiratory diseases. Their lead candidate (Ensifentrine) is a potential new class of drugs for the treatment of COPD (chronic obstructive pulmonary disease). This graph is essentially a binary bet on the success of this single drug, reflecting investor expectations regarding the FDA's decision and commercial launch.
AKIMA Market Segment Index - Pharma other
Verona Pharma is a biotech focused on a single goal: treating COPD (chronic obstructive pulmonary disease). Their key drug (Ensifentrine) is a potential blockbuster in this vast niche. This summary metric evaluates R&D. The chart shows the segment average. This benchmark: how does Verona's focused (COPD-only) approach differentiate it from the average pharma company?
The AKIM Index for the overall market
Verona Pharma is a biotech company focused on developing drugs to treat severe respiratory diseases (COPD). It's a high-risk scientific bet. This chart, reflecting the market average, provides a macro backdrop. It helps assess how this speculative story, driven by trial news, compares to overall economic trends.
